期刊
PITUITARY
卷 16, 期 1, 页码 91-100出版社
SPRINGER
DOI: 10.1007/s11102-012-0380-1
关键词
Non functioning pituitary adenomas; Dopamine receptor type 2; Vascular endothelial growth factor
资金
- Italian Ministry of University and Scientific and Technological Research
- Fondazione Cassa di Risparmio di Ferrara
- Associazione Ferrarese dell'Ipertensione Arteriosa
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Laboratorio in rete del Tecnopolo Tecnologie delle terapie avanzate (LTTA) of the University of Ferrara
Dopamine (DA) therapy of non-functioning pituitary adenomas (NFA) can result in tumor stabilization and shrinkage. However, the mechanism of action is still unknown. Previous evidence showed that DA can inhibit pituitary vascular endothelial growth factor expression (VEGF), that may be involved in pituitary tumor growth. The aim of our study was to clarify whether VEGF secretion modulation might mediate the effects of DA agonists on cell proliferation in human NFA. We assessed DA receptor subtype 2 (DR2) expression in 20 NFA primary cultures, where we also investigated the effects of a selective DR2 agonist, cabergoline (Cab), on VEGF secretion and on cell viability. All NFA samples expressed alpha-subunit and DR2 was expressed in 11 samples. In DR2 expressing tumors, Cab significantly reduced cell viability (-25%; P < 0.05) and VEGF secretion (-20%; P < 0.05). These effects were counteracted by treatment with the DA antagonist sulpiride. Cab antiproliferative effects were blocked by VEGF. Our data demonstrate that Cab, via DR2, inhibits cell viability also by reducing VEGF secretion in a selected group of NFA, supporting that DA agonists can be useful in the medical therapy of DR2 expressing NFA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据